Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
391,374
396,430
360,320
340,923
331,731
311,074
Total Accounts Receivable
335,349
339,841
358,106
320,803
327,924
362,741
Inventories
135,228
156,907
161,691
182,537
147,626
151,511
Other Current Assets
51,341
72,780
17,420
32,403
38,339
31,834
Total Current Assets
913,292
965,958
897,537
876,665
845,619
857,159
Net Property, Plant & Equipment
191,451
202,869
200,955
191,115
181,295
173,483
Total Investments and Advances
85,392
101,190
80,383
54,178
59,780
85,110
Long-Term Note Receivable
-
15,588
35,579
22,263
25,282
25,248
Intangible Assets
396,886
432,181
489,862
555,940
629,888
655,571
Other Assets
20,557
24,593
14,770
23,562
19,104
8,121
Total Assets
1,653,108
1,793,578
1,799,338
1,814,072
1,858,205
1,897,648
ST Debt & Current Portion LT Debt
397
365
505
499
444
Accounts Payable
187,032
226,602
181,559
182,826
140,909
Income Tax Payable
13,237
14,124
19,312
10,900
25,184
Other Current Liabilities
140,022
179,799
211,983
205,631
255,083
Total Current Liabilities
340,688
420,890
413,359
399,856
421,620
Long-Term Debt
749
626
722
1,136
904
Provision for Risks & Charges
41,519
48,894
62,196
59,262
60,323
Deferred Taxes
45,528
51,161
80,252
71,835
70,811
Other Liabilities
1,674
5,214
63,852
61,846
74,335
Total Liabilities
384,632
475,662
540,129
540,614
583,608
Common Equity (Total)
1,268,476
1,317,916
1,259,209
1,271,810
1,268,289
Total Shareholders' Equity
1,268,476
1,317,916
1,259,209
1,271,810
1,268,289
Total Equity
1,268,476
1,317,916
1,259,209
1,271,810
1,268,289
Liabilities & Shareholders' Equity
1,653,108
1,793,578
1,799,338
1,812,424
1,851,897

About Astellas Pharma

View Profile
Address
2-5-1 Nihonbashi-Honcho
Tokyo Tokyo 103
Japan
Employees -
Website http://www.astellas.com
Updated 07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.